Researchers study under-recognised and under-treated prothrombotic condition: High platelet reactivity despite treatment

May 6, 2013

Within the past decade, the variability in pharmacodynamic response and moderate antiplatelet efficacy of clopidogrel has raised major concerns, in particular because it is associated with an increased risk for ischemic events in PCI patients. Certainly, the public should have detailed knowledge about the incidence of high on-treatment platelet reactivity (HTPR) and its impact on clinical outcomes.

For this reason and to demonstrate how to diagnose and treat this pro-thrombotic condition, Prof. Dr. Kurt Huber, Director, 3rd Dept. Med., Cardiology and Emergency Medicine, Wilhelminen Hospital, Vienna, Austria, and Prof. Dr. Karsten Schör, Director em. Institute of Pharmacology and , Heinrich-Heine University Düsseldorf, Germany, and their co-authors have written a Theme Issue in the journal Thrombosis and Haemostasis, addressing various facets of HTPR.

HTPR - affecting non- or low-responders to treatment with P2Y12-receptor inhibitors (such as ) - is known to trigger stent-thrombosis, , and . The variability in response could be linked to impacting the activity of the cytochrome P450 enzyme in the liver. Underlying mechanisms seem to include and drug interactions (omeprazole and esomeprazole). Yet other agents lead to a lower rate of HTPR than clopidogrel. Therefore, regulatory agencies and cardiac societies suggest the use of other anti-platelet medications or alternative dosing strategies for clopidogrel in patients with reduced effectiveness to this P2Y12-receptor inhibitor.

The authors of the Theme Issue discuss the clinical value of new P2Y12-receptor inhibitors and also try to identify potential candidates who are most likely to benefit from the new agents.

In this Theme Issue which is part of the May issue of Thrombosis and Haemostasis, several reasons for "high on-treatment platelet reactivity" are reviewed. According to the Guest Editors Huber and Schör, researchers might benefit from the very latest 'state of the art' level of knowledge of pathophysiological pathways and detailed information about the pharmacodynamic and pharmacokinetic mechanisms of old and new P2Y12-receptor antagonists provided by this theme issue. Moreover, the novel diagnostic tests and therapeutic strategies discussed herein might also be interesting to health care providers as they would know which are the best tests to apply, how to direct a more critical use of available platelet function tests to detect HTPR; and to get to know which combination strategies are to be favored at present.

Explore further: Results of the TRIGGER-PCI trial reported at TCT 2011

More information: Huber K, Schör K: Theme Issue: High on-treatment platelet reactivity. Thromb Haemost 2013; 109: 789-853.

Related Stories

Results of the TRIGGER-PCI trial reported at TCT 2011

November 9, 2011

A clinical trial comparing prasugrel to clopidogrel for patients with high on-clopidogrel platelet reactivity (HCPR) following percutaneous coronary intervention (PCI) was ended early due to relatively few occurrences of ...

Global platelet reactivity and high risk ACS patients

August 28, 2012

Global platelet reactivity is more effective than responsiveness to clopidogrel in identifying acute coronary syndrome (ACS) patients at high risk of ischemic events, according to research presented at ESC Congress 2012.

Antiplatelets: 1 person, 1 dose?

April 14, 2011

An international consortium of scientists, including major contributions from the Montreal Heart Institute, demonstrates that the "one-size fits all" strategy of uniformly doubling the dose of an antiplatelet drug, clopidogrel, ...

30-day results of ADAPT-DES registry reported at TCT 2011

November 9, 2011

The relationship of platelet responsiveness to antiplatelet medications; and, the correlation of poor response, and overall platelet aggregation while on dual antiplatelet therapy to the risk of drug-eluting stent thrombosis ...

Recommended for you

Macrophages shown to be essential to a healthy heart rhythm

April 20, 2017

A Massachusetts General Hospital (MGH)-led research team has identified a surprising new role for macrophages, the white blood cells primarily known for removing pathogens, cellular debris and other unwanted materials. In ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.